Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,301,645 papers from all fields of science
Search
Sign In
Create Free Account
nonacog alfa
Known as:
Recombinant factor IX
, Factor IX (Recombinant)
, Coagulation factor IX (recombinant)
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
18 relations
Narrower (3)
BeneFIX
Mononine
Rixubis
Blood Coagulation Factor
Drug Allergy
Enzyme Activators [MoA]
Factor VII Deficiency
Expand
Broader (2)
coagulation factor IX, human
factor IX
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B
K. Fukutake
,
M. Taki
,
+4 authors
T. Karumori
Haemophilia
2019
Corpus ID: 174818271
In 2010, nonacog alfa became the first recombinant factor IX (rFIX) available in Japan for patients with haemophilia B.
2015
2015
Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes
P. Turecek
,
B. Abbühl
,
+13 authors
F. Scheiflinger
Expert Review of Clinical Pharmacology
2015
Corpus ID: 29678528
Nonacog gamma is a new recombinant factor IX to treat factor IX deficiency. It is indicated for control of bleeding episodes…
Expand
2014
2014
Novel, high incidence exercise-induced muscle bleeding model in hemophilia B mice: rationale, development and prophylactic intervention
M. Tranholm
,
A. Kristensen
,
M. Broberg
,
M. Groth
Journal of Thrombosis and Haemostasis
2014
Corpus ID: 18614620
Muscle hematomas are the second most common complication of hemophilia and insufficient treatment may result in serious and even…
Expand
2013
2013
Head‐to‐head comparison of the pharmacokinetic profiles of a high‐purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B
T. Lissitchkov
,
M. Matysiak
,
+8 authors
A. Páez
Haemophilia
2013
Corpus ID: 205153641
Head‐on comparative studies of factor IX (FIX) concentrates performed under standardized conditions are rarely conducted…
Expand
2013
2013
Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy
F. Shafer
,
L. Smith
,
N. Vendetti
,
P. Rendo
,
M. Carr
Haemophilia
2013
Corpus ID: 16986928
Spontaneous haemorrhage in patients with haemophilia is generally considered to occur randomly and without a predictable temporal…
Expand
Review
2011
Review
2011
Pioneering designs for recombinant coagulation factors.
S. Schulte
Thrombosis Research
2011
Corpus ID: 35048080
2004
2004
Purification of recombinant DNA-derived factor IX produced in transgenic pig milk and fractionation of active and inactive subpopulations.
M. Lindsay
,
G. Gil
,
Armando Cádiz
,
W. Velander
,
Chenming Zhang
,
K. V. Van Cott
Journal of Chromatography A
2004
Corpus ID: 21802750
2002
2002
Pharmacokinetics of Recombinant Factor IX after Intravenous and Subcutaneous Administration in Dogs and Cynomolgus Monkeys
K. McCarthy
,
P. Stewart
,
+5 authors
R. Schaub
Thrombosis and Haemostasis
2002
Corpus ID: 8016391
Summary Hemophilia B therapy requires intravenous (IV) infusions of large volumes of factor IX due to the low concentration of…
Expand
1998
1998
Viral safety of recombinant factor IX.
S. Adamson
,
T. Charlebois
,
B. O'Connell
,
W. Foster
Seminars in hematology (Print)
1998
Corpus ID: 25883466
The viral safety of Chinese hamster ovary (CHO)-cell-based pharmaceuticals is well established. There have been more than 100…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE